RAMP 201: A phase 2 study of avutometinib (VS-6766) ± defactinib in recurrent low-grade serous ovarian cancer (LGSOC).

Overview of attention for article published in Journal of Clinical Oncology, May 2023

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (96th percentile)
High Attention Score compared to outputs of the same age and source (93rd percentile)

Mentioned by

news: 8 news outlets
blogs: 1 blog

twitter: 6 X users

Readers on

mendeley: 23 Mendeley

So far, Altmetric has seen 6 X posts from 6 X users, with an upper bound of 194,195 followers.

RT @medical_xpress: New drug combination found to be twice as effective for some ovarian #cancer patients as next best treatment @icrnews h…

RT @VerastemOncolog: Thank you to Dr. @BanerjeeSusana @royalmarsdenNHS for sharing #RAMP201 data supporting avutometinib + defactinib as an…

RT @medical_xpress: New drug combination found to be twice as effective for some ovarian #cancer patients as next best treatment @icrnews h…

This page shows the most recent X posts that mention this research output. Click here to find out how to access more activity, including 2 additional X posts.